









Markets
/
Stocks
/
nasdaq-mlys
/

Mineralys Therapeutics Inc

MLYS

45.712USD

+1.212+2.72%

Market hours （ET）Quotes delayed by 15 min

3.00BMarket Cap

LossP/E TTM



Mineralys Therapeutics Inc

45.712

+1.212+2.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mineralys Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mineralys Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

194 / 501

Overall Ranking

339 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

45.000

Target Price

+18.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mineralys Therapeutics Inc Highlights

StrengthsRisks

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -11.37, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 76.00M shares, increasing 3.87% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 2.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.85.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Mineralys Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.69, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -11.37, which is -228.84% below the recent high of 14.65 and -109.29% above the recent low of -23.80.

Score

Industry at a Glance

Previous score

6.69

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 194/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Mineralys Therapeutics Inc is 44.50, with a high of 52.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

45.000

Target Price

+18.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Mineralys Therapeutics Inc

MLYS

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 8.85, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 45.13 and the support level at 35.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.42

Change

1.43

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.659

Neutral

RSI(14)

63.510

Neutral

STOCH(KDJ)(9,3,3)

56.699

Buy

ATR(14)

2.605

Low Volatility

CCI(14)

137.826

Buy

Williams %R

4.682

Overbought

TRIX(12,20)

0.029

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

39.798

Buy

MA10

40.095

Buy

MA20

41.223

Buy

MA50

39.099

Buy

MA100

26.617

Buy

MA200

19.970

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 100.62%, representing a quarter-over-quarter decrease of 4.60%. The largest institutional shareholder is The Vanguard, holding a total of 2.32M shares, representing 3.07% of shares outstanding, with 6.82% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Catalys Pacific, LLC

8.90M

RA Capital Management, LP

7.32M

+19.14%

Samsara BioCapital, LLC

5.67M

SR One Capital Management, LP

3.13M

The Vanguard Group, Inc.

Star Investors

2.32M

+13.93%

Capital International Investors

2.90M

Andera Partners S.A.S.

2.77M

-3.49%

BlackRock Institutional Trust Company, N.A.

2.74M

+24.18%

Integral Health Asset Management, LLC

2.70M

+17.39%

Capital World Investors

2.90M

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.